| Market Capitalization (Millions $) |
13,326 |
| Shares
Outstanding (Millions) |
778 |
| Employees |
265 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-856 |
| Cash Flow (TTM) (Millions $) |
-191 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Summit Therapeutics Inc is a biopharmaceutical company founded in 2003 and based in Cambridge, England, with additional offices in Oxford, UK, and Cambridge, Massachusetts, USA. It specializes in developing innovative therapies for rare and infectious diseases.
Summit's mission is to discover, develop and commercialize novel medicines that target some of the most challenging diseases in the world. The company has a particular focus on developing drugs with macrocyclic chemistry, which can be used to create highly specific and potent drugs that are efficient in treating specific diseases.
One of Summit's flagship products is Ridinilazole, an antibiotic drug that is being developed to treat Clostridioides difficile (CDI), a debilitating and challenging infection that affects millions of people worldwide. CDI is responsible for several deaths each year and is a major public health concern.
Ridinilazole has been shown to be more effective than the current standard of care, Vancomycin, and has fewer side effects. In clinical trials, the drug has demonstrated a higher cure rate and a lower rate of recurrence than Vancomycin.
Summit also has a partnership with Cyclica, a biotech company specializing in AI-driven drug discovery. The collaboration aims to develop macrocycle-derived drug candidates using Cyclica's Ligand Express platform to analyze and predict the binding affinity of large and complex molecules.
Summit's portfolio includes a pipeline of products in various stages of development, targeting conditions such as: Duchenne muscular dystrophy, Charcot-Marie-Tooth disease, Rett syndrome, and others. The company's research is supported by a team of experienced scientists and industry leaders, who have a proven track record of drug discovery and development.
In addition, the company works closely with international regulatory authorities, agencies and partners to advance its programs and ensure that they meet the highest standards of safety and efficacy.
Summit Therapeutics Inc is traded on the NASDAQ exchange under the symbol SMMT.
Company Address: 601 Brickell Key Drive, Suite 1000 Miami 33131 FL
Company Phone Number: 203-2034 Stock Exchange / Ticker: NASDAQ SMMT
|
4.57% 